Vamifeport

DB17692InvestigationalSmall molecule

Vamifeport is being investigated for the treatment of beta-thalassemia.

Chemical structure of Vamifeport
Mechanism
Curator reviewed
Formula / weight
C21H21FN6O2 · 408.437 g/mol (avg)
Also known as
2-(2-((2-(1h-benzimidazol-2-yl)ethyl)amino)ethyl)-n-((3-fluoropyridin-2-yl)methyl)-1,3-oxazole-4-carboxamide · 4-oxazolecarboxamide, 2-(2-((2-(1h-benzimidazol-2-yl)ethyl)amino)ethyl)-n-((3-fluoro-2-pyridinyl)methyl)-
Code names
VIT-2763

Resolves to

Compound
UNIIFUF66UD0KRCAS2095668-10-1ChEMBLCHEMBL4596566
Structure
InChIKeyKNYVRFXIVWUGBZ-UHFFFAOYSA-NSMILESFC1=CC=CN=C1CNC(=O)C1=COC(CCNCCC2=NC3=CC=CC=C3N2)=N1
Targets
Q9NP59SLC40A1

What you can answer from here — as of September 20, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Vamifeport, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In